BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 18729085)

  • 1. Dose-dependent growth inhibition in vivo of PC-3 prostate cancer with a reduction in tumoral growth factors after therapy with GHRH antagonist MZ-J-7-138.
    Heinrich E; Schally AV; Buchholz S; Rick FG; Halmos G; Mile M; Groot K; Hohla F; Zarandi M; Varga JL
    Prostate; 2008 Dec; 68(16):1763-72. PubMed ID: 18729085
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers.
    Stangelberger A; Schally AV; Varga JL; Hammann BD; Groot K; Halmos G; Cai RZ; Zarandi M
    Prostate; 2005 Aug; 64(3):303-15. PubMed ID: 15754342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of proliferation of PC-3 human prostate cancer by antagonists of growth hormone-releasing hormone: lack of correlation with the levels of serum IGF-I and expression of tumoral IGF-II and vascular endothelial growth factor.
    Plonowski A; Schally AV; Letsch M; Krupa M; Hebert F; Busto R; Groot K; Varga JL
    Prostate; 2002 Aug; 52(3):173-82. PubMed ID: 12111694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness of PC-3 human prostate cancer in nude mice.
    Stangelberger A; Schally AV; Varga JL; Zarandi M; Szepeshazi K; Armatis P; Halmos G
    Clin Cancer Res; 2005 Jan; 11(1):49-57. PubMed ID: 15671527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma.
    Szereday Z; Schally AV; Varga JL; Kanashiro CA; Hebert F; Armatis P; Groot K; Szepeshazi K; Halmos G; Busto R
    Cancer Res; 2003 Nov; 63(22):7913-9. PubMed ID: 14633721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular mechanisms of growth inhibition of human endometrial cancer cell line by an antagonist of growth hormone-releasing hormone.
    Zhao L; Yano T; Osuga Y; Nakagawa S; Oishi H; Wada-Hiraike O; Tang X; Yano N; Kugu K; Schally AV; Taketani Y
    Int J Oncol; 2008 Mar; 32(3):593-601. PubMed ID: 18292936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers.
    Stangelberger A; Schally AV; Zarandi M; Heinrich E; Groot K; Havt A; Kanashiro CA; Varga JL; Halmos G
    Prostate; 2007 Sep; 67(12):1339-53. PubMed ID: 17624923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins.
    Stangelberger A; Schally AV; Rick FG; Varga JL; Baker B; Zarandi M; Halmos G
    Prostate; 2012 Apr; 72(5):555-65. PubMed ID: 21796649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of growth of experimental human endometrial cancer by an antagonist of growth hormone-releasing hormone.
    Engel JB; Keller G; Schally AV; Toller GL; Groot K; Havt A; Armatis P; Zarandi M; Varga JL; Halmos G
    J Clin Endocrinol Metab; 2005 Jun; 90(6):3614-21. PubMed ID: 15784701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer.
    Muñoz-Moreno L; Arenas MI; Schally AV; Fernández-Martínez AB; Zarka E; González-Santander M; Carmena MJ; Vacas E; Prieto JC; Bajo AM
    Int J Cancer; 2013 Feb; 132(4):755-65. PubMed ID: 22777643
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.
    Papadia A; Schally AV; Halmos G; Varga JL; Seitz S; Buchholz S; Rick F; Zarandi M; Bellyei S; Treszl A; Szalontay L; Lucci JA
    Horm Metab Res; 2011 Oct; 43(11):816-20. PubMed ID: 22009378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers.
    Szepeshazi K; Schally AV; Groot K; Armatis P; Halmos G; Herbert F; Szende B; Varga JL; Zarandi M
    Br J Cancer; 2000 May; 82(10):1724-31. PubMed ID: 10817510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antagonists of growth-hormone-releasing hormone: an emerging new therapy for cancer.
    Schally AV; Varga JL; Engel JB
    Nat Clin Pract Endocrinol Metab; 2008 Jan; 4(1):33-43. PubMed ID: 18084344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers.
    Klukovits A; Schally AV; Szalontay L; Vidaurre I; Papadia A; Zarandi M; Varga JL; Block NL; Halmos G
    Cancer; 2012 Feb; 118(3):670-80. PubMed ID: 21751186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of acute and chronic administration of a new potent antagonist of growth hormone-releasing hormone in rats: mechanisms of action.
    Kovacs M; Zarándi M; Halmos G; Groot K; Schally AV
    Endocrinology; 1996 Dec; 137(12):5364-9. PubMed ID: 8940358
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of prostate-specific antigen (PSA) gene expression and release in LNCaP prostate cancer by antagonists of growth hormone-releasing hormone and vasoactive intestinal peptide.
    Rekasi Z; Schally AV; Plonowski A; Czompoly T; Csernus B; Varga JL
    Prostate; 2001 Aug; 48(3):188-99. PubMed ID: 11494334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice.
    Chatzistamou I; Schally AV; Varga JL; Groot K; Armatis P; Busto R; Halmos G
    J Clin Endocrinol Metab; 2001 May; 86(5):2144-52. PubMed ID: 11344219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Triple-negative breast cancers express receptors for growth hormone-releasing hormone (GHRH) and respond to GHRH antagonists with growth inhibition.
    Köster F; Engel JB; Schally AV; Hönig A; Schröer A; Seitz S; Hohla F; Ortmann O; Diedrich K; Buchholz S
    Breast Cancer Res Treat; 2009 Jul; 116(2):273-9. PubMed ID: 18629632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers.
    Seitz S; Rick FG; Schally AV; Treszl A; Hohla F; Szalontay L; Zarandi M; Ortmann O; Engel JB; Buchholz S
    Oncol Rep; 2013 Jul; 30(1):413-8. PubMed ID: 23624870
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective treatment of experimental human non-Hodgkin's lymphomas with antagonists of growth hormone-releasing hormone.
    Keller G; Schally AV; Groot K; Toller GL; Havt A; Köster F; Armatis P; Halmos G; Zarandi M; Varga JL; Engel JB
    Proc Natl Acad Sci U S A; 2005 Jul; 102(30):10628-33. PubMed ID: 16027368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.